Barry S. Coller, MD
Barry S. Coller, MD joined Rockefeller University in 2001 as the David Rockefeller Professor of Medicine, Vice President for Medical Affairs, and Head of the Laboratory of Blood and Vascular Biology. He previously served as the Murray M. Rosenberg Professor of Medicine and Chairman of the Samuel Bronfman Department of Medicine at Mount Sinai School of Medicine from 1993-2001.
Dr. Coller’s research has focused on hemostasis and thrombosis, in particular platelet physiology. He developed a monoclonal antibody that inhibits platelet function and worked with scientists at Centocor to develop it into the drug abciximab, which was approved by the FDA in 1994 to prevent ischemic complications of percutaneous coronary interventions. More than 5.0 million patients have been treated with abciximab. He also developed an assay to assess platelet function, and FDA-approved automated derivatives of that assay (VerifyNow) are used in the U.S. Europe, and countries in Asia. Most recently he has developed a small molecule platelet inhibitor (zalunfiban) that is in Phase 3 testing for first-point-of-contact therapy of myocardial infarction. Dr. Coller is the recipient or a co-recipient of twenty-three U.S. patents.
For his scientific achievements, Dr. Coller was awarded the Robert J. and Claire Pasarow Foundation Award in 2005, the Warren Alpert Foundation Award in 2001, and a National Research Achievement Award from the American Heart Association in 1998. He is a member of the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Coller served as the President of the American Society of Hematology in 1998 and founding President of the Society for Clinical and Translational Science.